CJC-1295 No Dac + Ipamorelin

CJC-1295 No DAC + Ipamorelin – Growth Hormone Signalling Research Peptide Combination

For Professional Research Use Only

CJC-1295 No DAC + Ipamorelin is a dual-peptide research formulation designed for advanced investigation into growth hormone (GH) signalling, pulsatile secretion patterns, and endocrine regulation.

This combination pairs CJC-1295 No DAC, a growth hormone–releasing hormone (GHRH) analogue, with Ipamorelin, a selective growth hormone secretagogue. Together, they are studied for their complementary roles in stimulating endogenous GH release while maintaining controlled and physiologically relevant signalling dynamics.

What Is CJC-1295 No DAC + Ipamorelin?

CJC-1295 No DAC + Ipamorelin is a synergistic peptide pairing used in laboratory research to explore coordinated GH pathway activation.

• CJC-1295 No DAC is a short-acting GHRH analogue studied for its ability to stimulate natural, pulsatile GH release without prolonged receptor binding.

• Ipamorelin is a ghrelin receptor agonist known for its selective GH secretagogue activity with minimal interaction with other endocrine pathways.

Unlike long-acting GH analogues, this combination allows researchers to study timed, pulse-based GH signalling in controlled research environments.

Key Research Applications

CJC-1295 No DAC + Ipamorelin is commonly studied in research models focused on:

• Growth hormone secretion dynamics

• Pulsatile endocrine signalling research

• Muscle growth and recovery models

• Tissue repair and regeneration studies

• Metabolic signalling and nutrient partitioning research

• Anti-catabolic pathway investigation

Its short-acting and selective profile makes it especially valuable for studies requiring precise GH release timing.

Mechanism of Action

This peptide combination operates through dual but complementary mechanisms:

• CJC-1295 No DAC binds to GHRH receptors, stimulating the pituitary to release growth hormone in a natural pulse pattern.

• Ipamorelin activates ghrelin receptors, amplifying GH release without significant stimulation of cortisol or prolactin pathways.

Together, they promote coordinated GH signalling while preserving physiological feedback mechanisms in research models.

Scientific & Research Insight

Laboratory research on these peptides indicates that their combined use may:

• Enhance endogenous GH pulse amplitude

• Support anabolic signalling without prolonged receptor overstimulation

• Improve research outcomes related to tissue repair and recovery

• Allow controlled investigation of GH-dependent metabolic pathways

This makes the combination a widely studied tool in endocrine and growth-related research protocols.

Product Composition

• CJC-1295 No DAC: 5 mg

• Ipamorelin: 5 mg

Supplied as a precision-measured peptide combination for laboratory research consistency.

Product Quality & Purity

• Third-party lab tested

• ≥99% purity (individual components)

• Batch-verified for reproducibility

• Manufactured under strict quality control standards

• Designed for reliable research outcomes

Each batch is produced to ensure consistency across experimental applications.

Important Research Disclaimer

This product is strictly for laboratory and research use only.

• Not approved for human or veterinary consumption

• Not a dietary supplement or pharmaceutical product

• Intended solely for controlled research environments

• Purchasers must be 18+ and comply with all applicable regulations

Storage Guidelines

• Store lyophilised product in a freezer

• Refrigerate reconstituted solutions at 2–8°C

• Maintain sterile handling conditions to preserve research integrity

Why Choose Us?

• Premium-grade research peptide formulations

• Fast and discreet shipping

• Reliable supply for long-term research projects

Summary

CJC-1295 No DAC + Ipamorelin is a research peptide combination designed for advanced investigation into growth hormone signalling and pulsatile secretion. Its short-acting, selective profile makes it a valuable tool for endocrine, regenerative, and metabolic research requiring precise GH pathway control.